VTRS Price Prediction Next Week
Based on the provided data and technical analysis, here's the price prediction for VTRS for the next trading week:
Technical Analysis
- Current RSI (14) at 29.12 indicates oversold conditions
- MACD shows bearish momentum with -0.32
- Stock trading below all major moving averages (5,10,20,60,200-day)
- Bollinger Bands show price near lower band (10.44), suggesting potential bounce
News Impact According to recent reports, VTRS has significantly underperformed the broader market:
- Down 12.5% YTD in 2025
- Lagging behind SPX's 2.7% rise
- Recent Q3 earnings beat expectations with $3.75B revenue and $0.75 EPS
- Full-year 2024 guidance projects 2% revenue growth
Price Targets
- Current price: $10.77
- Analyst consensus target: $13.17 (20.9% upside)
- Street-high target: $15.00 (37.7% upside)
- Fibonacci levels indicate:
- Resistance: $11.43 (R1), $11.62 (R2)
- Support: $10.79 (S1), $10.60 (S2)
Next Week's Price Prediction Expected trading range: $10.60 - $11.43 Most likely scenario: Initial bounce from oversold conditions toward first resistance at $11.43, followed by consolidation around $11.00.
Recommendation: BUY at current levels ($10.77) with stop loss at $10.44 (lower Bollinger Band). The oversold conditions and positive analyst outlook suggest a potential short-term recovery.
VTRS Similar Chart Price Prediction
The price of VTRS is predicted to go up -1.52%, based on the high correlation periods with NX. The similarity of these two price pattern on the periods is 98.62%.
VTRS
NX
Down: -1.52%Similarity: 98.62%
VTRS Revenue Forecast
VTRS EPS Forecast
VTRS FAQs
What is bull’s view on VTRS?
What is bear's view on VTRS?
What is VTRS revenue forecast for next quarter？
What is VTRS eps forecast for next quarter？
VTRS VS S&P500
A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power.
Effective portfolio optimization and a promising pipeline of first-to-market launches will provide solid top line tailwinds.
Exiting biosimilars business will reallocate resources and help the company focus on long-term goals in its core generic and branded markets.
VTRS Analyst's Forecast
David Amsellem
Piper Sandler
Hold
2024-12-06
Price Target
$13 → $14
Upside
+10.06%
Piper Sandler raised the firm's price target on Viatris to $14 from $13 and keeps a Neutral rating on the shares following the firm's annual healthcare conference. Piper continues to believe that to the extent that Viatris is going to see multiple expansion over time, it will take clinical/regulatory success on "innovative" brand assets.
Balaji Prasad
Barclays
Sell
2024-11-08
Price Target
$11 → $12
Downside
-7.41%
